Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans
Open Access
- 26 August 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in npj Vaccines
- Vol. 5 (1), 1-10
- https://doi.org/10.1038/s41541-020-00227-x
Abstract
Although traditional egg-based inactivated influenza vaccines can protect against infection, there have been significant efforts to develop improved formats to overcome disadvantages of this platform. Here, we have assessed human CD4 T cell responses to a traditional egg-based influenza vaccine with recently available cell-derived vaccines and recombinant baculovirus-derived vaccines. Adults were administered either egg-derived Fluzone(R), mammalian cell-derived Flucelvax(R)or recombinant HA (Flublok(R)). CD4 T cell responses to each HA protein were assessed by cytokine EliSpot and intracellular staining assays. The specificity and magnitude of antibody responses were quantified by ELISA and HAI assays. By all criteria, Flublok vaccine exhibited superior performance in eliciting both CD4 T cell responses and HA-specific antibody responses, whether measured by mean response magnitude or percent of responders. Although the mechanism(s) underlying this advantage is not yet clear, it is likely that both qualitative and quantitative features of the vaccines impact the response.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400005C)
This publication has 74 references indexed in Scilit:
- Glycan-Dependent Immunogenicity of Recombinant Soluble Trimeric HemagglutininJournal of Virology, 2012
- TLR7 Recognition Is Dispensable for Influenza Virus A Infection but Important for the Induction of Hemagglutinin-Specific Antibodies in Response to the 2009 Pandemic Split Vaccine in MiceJournal of Virology, 2012
- Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adultsVaccine, 2011
- The need for quadrivalent vaccine against seasonal influenzaVaccine, 2010
- Assessment of Seasonal Influenza A Virus-Specific CD4 T-Cell Responses to 2009 Pandemic H1N1 Swine-Origin Influenza A VirusJournal of Virology, 2010
- Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4+ T-cell responses to internal proteins, hemagglutinins, and neuraminidasesHuman Immunology, 2009
- Influenza control in the 21st century: Optimizing protection of older adultsVaccine, 2009
- FluBlok, a next generation influenza vaccine manufactured in insect cellsBiologicals, 2009
- In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responsesVaccine, 2009
- Influenza A Virus Matrix Protein 1-Specific Human CD8+T-Cell Response Induced in Trivalent Inactivated Vaccine RecipientsJournal of Virology, 2008